Egetis Therapeutics AB (publ) (EGTX.ST)
SEK 4.09
(1.11%)
SEK 4.09
(1.11%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 193.5 Million SEK | 253.75% |
| 2022 | 54.7 Million SEK | 16.88% |
| 2021 | 46.79 Million SEK | 39.1% |
| 2020 | 33.64 Million SEK | -8.9% |
| 2019 | 36.93 Million SEK | 17.77% |
| 2018 | 31.35 Million SEK | 18.23% |
| 2017 | 26.52 Million SEK | 41.98% |
| 2016 | 18.68 Million SEK | 2.73% |
| 2015 | 18.18 Million SEK | 189.86% |
| 2014 | 6.27 Million SEK | 4.08% |
| 2013 | 6.02 Million SEK | -20.8% |
| 2012 | 7.61 Million SEK | -77.76% |
| 2011 | 34.22 Million SEK | 799.89% |
| 2010 | 3.8 Million SEK | 83.01% |
| 2009 | 2.07 Million SEK | 94.14% |
| 2008 | 1.07 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 86.1 Million SEK | 11.83% |
| 2024 Q1 | 76.9 Million SEK | 45.37% |
| 2023 FY | 193.5 Million SEK | 253.75% |
| 2023 Q2 | 43.3 Million SEK | 38.78% |
| 2023 Q1 | 31.2 Million SEK | 39.91% |
| 2023 Q3 | 44.9 Million SEK | 3.7% |
| 2023 Q4 | 52.9 Million SEK | 17.82% |
| 2022 Q1 | 14.55 Million SEK | -0.68% |
| 2022 FY | 54.7 Million SEK | 16.88% |
| 2022 Q4 | 22.3 Million SEK | 79.84% |
| 2022 Q3 | 12.4 Million SEK | -19.95% |
| 2022 Q2 | 15.49 Million SEK | 6.42% |
| 2021 Q2 | 11.04 Million SEK | -2.29% |
| 2021 Q3 | 9.78 Million SEK | -11.46% |
| 2021 Q4 | 14.65 Million SEK | 49.8% |
| 2021 Q1 | 11.3 Million SEK | 3.45% |
| 2021 FY | 46.79 Million SEK | 39.1% |
| 2020 Q2 | 7.09 Million SEK | -9.73% |
| 2020 FY | 33.64 Million SEK | -8.9% |
| 2020 Q4 | 10.93 Million SEK | 44.88% |
| 2020 Q1 | 7.86 Million SEK | -27.16% |
| 2020 Q3 | 7.54 Million SEK | 6.33% |
| 2019 Q1 | 8.31 Million SEK | -5.33% |
| 2019 FY | 36.93 Million SEK | 17.77% |
| 2019 Q2 | 9.99 Million SEK | 20.3% |
| 2019 Q3 | 7.83 Million SEK | -21.68% |
| 2019 Q4 | 10.79 Million SEK | 37.83% |
| 2018 Q3 | 6.81 Million SEK | -15.18% |
| 2018 Q4 | 8.77 Million SEK | 28.82% |
| 2018 FY | 31.35 Million SEK | 18.23% |
| 2018 Q1 | 7.72 Million SEK | -12.46% |
| 2018 Q2 | 8.03 Million SEK | 3.99% |
| 2017 FY | 26.52 Million SEK | 41.98% |
| 2017 Q4 | 8.82 Million SEK | 26.3% |
| 2017 Q3 | 6.98 Million SEK | 27.89% |
| 2017 Q2 | 5.46 Million SEK | 4.29% |
| 2017 Q1 | 5.24 Million SEK | -0.02% |
| 2016 Q1 | 4.95 Million SEK | -63.06% |
| 2016 FY | 18.68 Million SEK | 2.73% |
| 2016 Q4 | 5.24 Million SEK | 24.43% |
| 2016 Q3 | 4.21 Million SEK | -1.36% |
| 2016 Q2 | 4.27 Million SEK | -13.82% |
| 2015 Q3 | 1.15 Million SEK | 17.31% |
| 2015 FY | 18.18 Million SEK | 189.86% |
| 2015 Q1 | 2.63 Million SEK | 27.08% |
| 2015 Q2 | 982 Thousand SEK | -62.76% |
| 2015 Q4 | 13.41 Million SEK | 1064.32% |
| 2014 Q2 | 1.41 Million SEK | 22.04% |
| 2014 Q1 | 1.15 Million SEK | -28.36% |
| 2014 Q4 | 2.07 Million SEK | 27.22% |
| 2014 Q3 | 1.63 Million SEK | 15.51% |
| 2014 FY | 6.27 Million SEK | 4.08% |
| 2013 Q2 | 1.57 Million SEK | 7.38% |
| 2013 FY | 6.02 Million SEK | -20.8% |
| 2013 Q4 | 1.61 Million SEK | 17.11% |
| 2013 Q3 | 1.37 Million SEK | -12.22% |
| 2013 Q1 | 1.46 Million SEK | 107.68% |
| 2012 Q2 | 10.91 Million SEK | 15.66% |
| 2012 FY | 7.61 Million SEK | -77.76% |
| 2012 Q4 | -19.05 Million SEK | -401.58% |
| 2012 Q3 | 6.31 Million SEK | -42.09% |
| 2012 Q1 | 9.43 Million SEK | -63.84% |
| 2011 Q2 | 2.5 Million SEK | -11.71% |
| 2011 Q1 | 2.84 Million SEK | 76.55% |
| 2011 Q4 | 26.08 Million SEK | 836.38% |
| 2011 FY | 34.22 Million SEK | 799.89% |
| 2011 Q3 | 2.78 Million SEK | 11.08% |
| 2010 Q2 | 757.8 Thousand SEK | 43.95% |
| 2010 Q1 | 526.42 Thousand SEK | 0.0% |
| 2010 Q4 | 1.6 Million SEK | 76.86% |
| 2010 FY | 3.8 Million SEK | 83.01% |
| 2010 Q3 | 909.86 Thousand SEK | 20.07% |
| 2009 FY | 2.07 Million SEK | 94.14% |
| 2008 FY | 1.07 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 87.221% |
| Camurus AB (publ) | 1.05 Billion SEK | 81.739% |
| Mendus AB (publ) | 129.13 Million SEK | -49.841% |
| Lipum AB (publ) | 37.3 Million SEK | -418.669% |
| NextCell Pharma AB | -576.01 Thousand SEK | 33692.642% |
| Simris Alg AB (publ) | 38.64 Million SEK | -400.75% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -583.11% |
| Active Biotech AB (publ) | 44.8 Million SEK | -331.833% |
| Amniotics AB (publ) | 29.07 Million SEK | -565.589% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -1220.549% |
| BioArctic AB (publ) | 89.62 Million SEK | -115.895% |
| Cantargia AB (publ) | 290.01 Million SEK | 33.28% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -783.763% |
| CombiGene AB (publ) | 44.14 Million SEK | -338.337% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | -35.327% |
| Genovis AB (publ.) | 88.19 Million SEK | -119.395% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | -68.154% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -2562.356% |
| Intervacc AB (publ) | 79.78 Million SEK | -142.527% |
| Kancera AB (publ) | 63.07 Million SEK | -206.768% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -3406.07% |
| LIDDS AB (publ) | 27.75 Million SEK | -597.247% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -2567.494% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | -42.372% |
| OncoZenge AB (publ) | 15.9 Million SEK | -1116.599% |
| Saniona AB (publ) | 1.07 Million SEK | -17866.574% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 39.814% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 45.893% |
| Xintela AB (publ) | 57.31 Million SEK | -237.602% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | -6.474% |
| Ziccum AB (publ) | 27.87 Million SEK | -594.096% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -1079.806% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 36.989% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -353.884% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -994.271% |
| Corline Biomedical AB | 30.16 Million SEK | -541.408% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -233.442% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -132.659% |
| Aptahem AB (publ) | 10.01 Million SEK | -1832.499% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | -43.659% |
| Fluicell AB (publ) | 28.61 Million SEK | -576.172% |
| Biovica International AB (publ) | 133.72 Million SEK | -44.703% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -877.767% |
| AcouSort AB (publ) | 25.87 Million SEK | -647.797% |
| Abliva AB (publ) | 27.86 Million SEK | -594.395% |
| 2cureX AB (publ) | 36.51 Million SEK | -429.876% |
| I-Tech AB | 40.14 Million SEK | -381.967% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 77.486% |
| Cyxone AB (publ) | 28.21 Million SEK | -585.83% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | -76.926% |
| Biosergen AB | 26.8 Million SEK | -621.773% |
| Nanologica AB (publ) | 69.88 Million SEK | -176.876% |
| SynAct Pharma AB | 224.49 Million SEK | 13.807% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -338.021% |
| BioInvent International AB (publ) | 441.4 Million SEK | 56.163% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -707.789% |
| Alzinova AB (publ) | 36.39 Million SEK | -431.652% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 33.217% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -2363.001% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | -74.459% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -1216.327% |